David Aggen, MD
davidaggen.bsky.social
David Aggen, MD
@davidaggen.bsky.social
Genitourinary Oncologist, NYC
Variant histologies in bladder cancer are like different genres of music

Same stage - different openers and headliners

Watch here ➡️ x.com/uromigos/sta...
October 25, 2025 at 1:15 AM
If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here!

shorturl.at/uTCUA
April 25, 2025 at 2:10 PM
Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25
February 15, 2025 at 1:58 AM
Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with

ORR of 41%
DCR 90%
50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor

@MSKCancerCenter #ASCOGU #GU25
February 15, 2025 at 12:09 AM
Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25

Path Cr rate of 84.6% in HER2 3+
February 14, 2025 at 5:19 PM
Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer
January 24, 2025 at 8:24 PM
January 24, 2025 at 2:35 PM
Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session
January 23, 2025 at 9:04 PM
Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer
January 23, 2025 at 6:34 PM
Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer
January 23, 2025 at 4:55 PM
#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz

Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis

@urotoday
December 4, 2024 at 11:30 PM